JAK2-specific inhibitors have been developed for the treatment of hematological malignancy, although are omitted here for simplicity. Source: Modified from Baker KF, et al. Ann Rheum Dis. 2018;77 ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

A new study published in the journal of Arthritis & Rheumatology showed that Janus kinase (JAK) inhibitors did not increase ...

Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016 provides comprehensive insights about pipeline drugs across this Mechanism of action. Key objective ...

Janus kinase, or JAK, inhibitors have been used in the treatment of rheumatological disorders, including psoriatic arthritis. Their benefit in psoriatic skin disease is still being studied ...

Janus kinase inhibitors may treat vitiligo Publish Date June 28, 2015 HealthDay News — Researchers report that a drug for rheumatoid arthritis may be a promising treatment for vitiligo.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTP-543 (Concert Pharmaceuticals), an oral Janus kinase (JAK) inhibitor for alopecia areata.

The paper, “Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study,” is available (at midnight on November 1 st ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...